Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.
2018Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins
Gresch, G.; Schenke, L.; Mladenov, R.; Zwirner, S.; Cremer, C.; Niesen, J.; Grieger, E.; Brümmendorf, T.; Jost, E.; Fischer, R.; Stockmeyer, B.; Barth, S.; Nachreiner, T.; Stein, C.
Zeitschriftenaufsatz
2017Generation of an artificial human B cell line test system using Transpo-mAb (TM) technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins
Klose, D.; Woitok, M.; Niesen, J.; Beerli, R.R.; Grawunder, U.; Fischer, R.; Barth, S.; Fendel, R.; Nachreiner, T.
Zeitschriftenaufsatz
2016Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy
Cong, X.; Cremer, C.; Nachreiner, T.; Barth, S.; Caloni, P.
Zeitschriftenaufsatz
2016Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model
Amoury, M.; Kolberg, K.; Pham, A.-T.; Hristodorov, D.; Mladenov, R.; Fiore, S. di; Helfrich, W.; Kiessling, F.; Fischer, R.; Pardo, A.; Thepen, T.; Hussain, A.F.; Nachreiner, T.; Barth, S.
Zeitschriftenaufsatz
2016A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
Amoury, M.; Mladenov, R.; Nachreiner, T.; Pham, A.-T.; Hristodorov, D.; Di Fiore, S.; Helfrich, W.; Pardo, A.; Fey, G.; Schwenkert, M.; Thepen, T.; Kiessling, F.; Hussain, A.F.; Fischer, R.; Kolberg, K.; Barth, S.
Zeitschriftenaufsatz
2016Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen
Klose, D.; Saunders, U.; Barth, S.; Fischer, R.; Jacobi, A.M.; Nachreiner, T.
Zeitschriftenaufsatz
2015Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential
Cremer, C.; Vierbuchen, T.; Hein, L.; Fischer, R.; Barth, S.; Nachreiner, T.
Zeitschriftenaufsatz
2015Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins
Cremer, C.; Hehmann-Titt, G.; Schiffer, S.; Melmer, G.; Carloni, P.; Barth, S.; Nachreiner, T.
Aufsatz in Buch
2015Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo
Cremer, C.; Braun, H.; Mladenov, R.; Schenke, L.; Cong, X.; Jost, E.; Brümmendorf, T.H.; Fischer, R.; Carloni, P.; Barth, S.; Nachreiner, T.
Zeitschriftenaufsatz
2013SNAP-tag based agents for preclinical In vitro imaging in malignant diseases
Amoury, M.; Blume, T.; Brehm, H.; Niesen, J.; Tenhaef, N.; Barth, S.; Gattenlohner, S.; Helfrich, W.; Fitting, J.; Nachreiner, T.; Pardo, A.
Zeitschriftenaufsatz
2009Antigen-specific depletion of autoreactive B lymphocytes in multiple sclerosis
Nachreiner, T.
Dissertation
2009Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-Alkylguanine DNA alkyltransferase
Kampmeier, F.; Ribbert, M.; Nachreiner, T.; Dembski, S.; Beaufils, F.; Brecht, A.; Barth, S.
Zeitschriftenaufsatz
2008Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin
Nachreiner, T.; Kampmeier, F.; Thepen, T.; Fischer, R.; Barth, S.; Stocker, M.
Zeitschriftenaufsatz
2005Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins
Stöcker, M.; Klockenbring, T.; Huhn, M.; Nachreiner, T.; Wicklein, D.; Petersen, A.; Bauer, R.; Goerlich, R.; Fischer, R.; Barth, S.
Zeitschriftenaufsatz